Stock Ratings / Health Care / ATOS / forecast

AYTU (41) BYSI (42) TXMD (48) QNTM (58) ⌘ Pro Terminal →

Atossa Therapeutics Inc. (ATOS) 12-Month Stock Forecast & Price Target Cone

$2.23 -5.91% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.20

Atossa Therapeutics Inc. (ATOS) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $22.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.20 (-1.25%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ATOS)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (36/100 Composite)

🔍 WHY ATOS SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (28% of score)

FRED Regime × Technicals: 4% of 52W Range • RSI-14 at 40.3 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$2.44+19.3% Next Q

Q2 (-2Q)

Grade D$2.91-10.7% Next Q

Q3 (-1Q)

Grade E$2.60-14.2% Next Q

Current

Grade D-$2.23-8.3% Hist 90D α

Trajectory: D (44) → D- (36)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ATOS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ATOS currently carries a cautious 36/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.42) and Max Pain ($2.34) forces dealer call-delta covering toward $15.59.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ATOS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ATOS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 36%NO 64%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your ATOS Position Size: $10,000

Shares at $2.23: 4484.3 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $1.57

$7,040

$-2,960 (-29.6%)

12M Consensus BaseTarget $2.01

$9,013

$-987 (-9.9%)

12M Bull Case BreakoutTarget $15.59

$69,910

+$59,910 (+599.1%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$2	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$15	69%	B
JP MorganUS Large-Cap Research	SELL	$2	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ATOS)

✓Walkthrough of ATOS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ATOS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -58.47%📐 HORIZONTAL RANGE

2026-10-30O $2.25H $2.43L $2.14C $2.23VOL 32.9K

RES: $3.16SUP: $1.68SMA50: $2.42SMA200: $3.95

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ATOS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ATOS Butterfly Map → + Track ATOS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ATOS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ATOS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ATOS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ATOS)

Health Care Rank #796 of 1016 ⚔️ AYTU vs ATOS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ATOS vs. AYTU, BYSI, TXMD, QNTM)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Atossa Therapeutics Inc. (ATOS) ranks #796 by composite RQD confidence (36/100, grade D-) and #824 by equity capitalization ($22.3M). Within this direct 5-issuer industry benchmark cohort, ATOS leads on earnings valuation at N/A trailing P/E, while TXMD leads on capital efficiency and profitability with -12.9% ROIC and — gross margin. QNTM currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with ATOS at 36/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ATOS ACTIVE Atossa Therapeutics Inc.	D-	36/100	—	—	-35.0%	-5.91%	$22.3M	Benchmark Subject
AYTU Aytu BioPharma Inc.	D-	41/100	—	69.0%	-35.0%	+0.51%	$21.5M	/aytu-vs-atos →
BYSI BeyondSpring Inc.	D-	42/100	—	—	-35.0%	-1.49%	$21.2M	/bysi-vs-atos →
TXMD TherapeuticsMD Inc.	D	48/100	—	—	-12.9%	+2.24%	$21.2M	/txmd-vs-atos →
QNTM Quantum Biopharma Ltd. Class B Subordinate Voting Shares	D+	58/100	—	—	—	+2.95%	$20.7M	/qntm-vs-atos →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001488039

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Atossa Therapeutics Inc. (ATOS) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$34.8M, operating cash flow of -$29.8M, and free cash flow of -$29.8M (-41.5% YoY). On the balance sheet, ATOS closed FY2025 with $47.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$34.8M	-$29.8M	-$29.8M	$47.6M	—
FY2024 (FY)	2024-12-31	$0	-$25.5M	-$21.0M	-$21.0M	$76.4M	—
FY2023 (FY)	2023-12-31	$0	-$30.1M	-$20.9M	-$20.9M	—	—

3. ATOS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ATOS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Atossa Therapeutics Inc. (NASDAQ: ATOS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $2.23 (-5.91% 1D, market cap $22.3M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ATOS ranks #796 in composite RQD confidence.

How does ATOS compare to AYTU and BYSI in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ATOS carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, AYTU (Aytu BioPharma Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $21.5M) and BYSI (BeyondSpring Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $21.2M). Among the 5-stock peer group, ATOS leads on earnings multiple (N/A) while TXMD leads on capital efficiency (-12.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ATOS?

Per ATOS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001488039), Atossa Therapeutics Inc. generated $0 in revenue, -$34.8M in net income, and -$29.8M in free cash flow against $47.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ATOS trading relative to its 50-day, 200-day, and 52-week technical levels?

ATOS last traded at $2.23 (-5.91% on volume of 68,017 shares), positioning the stock -7.85% below its 50-day simple moving average ($2.42) and -43.54% below its 200-day simple moving average ($3.95). Across its 52-week range of $1.70 to $14.85, ATOS sits at the 4.0% percentile with a 14-day RSI of 40.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.95 to $2.51).

ATOS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is ATOS's 12-month stock price target?

Atossa Therapeutics Inc. (ATOS) carries a 12-month consensus base price target of $2.01 (-9.9% from $2.23), with a bull-case target of $15.59 and a bear-case floor of $1.57.

Is ATOS stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates ATOS D- (Sell — SELL) with an RQD Confidence score of 36/100.

Direct Sub-Reports: ATOS RQD Cockpit ATOS 12M Forecast ATOS Earnings & Move ATOS Dividends & DRIP ATOS Insiders & 13F ATOS Whale Options ATOS Profit Sankey ATOS News & Why